Global healthcare and life sciences team represents the international biopharmaceutical company in the agreement.
Sobi (STO: SOBI) and Enable Injections, Inc. have announced a global (ex-US) development agreement and supply agreement across Sobi territories for the enFuse Injector, for the subcutaneous delivery of Aspaveli (pegcetacoplan).
Latham & Watkins LLP advised Sobi in the transaction with a corporate deal team led by San Diego partner Steve Chinowsky, London associate Oliver Mobasser, and San Diego counsel Darryl Steensma.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
